Incyte Corporation
Wilmington, DE
- UEI
- ZTM9U2G5VTK8
- CAGE
- 1F8A9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1801 Augustine Cut Off, Wilmington, DE 19803, USA
- Website
- incyte.com
- Founded
- 2002
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $121,144 |
| FY2023 | $102,208 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pemigatinib | Veterans Integrated Service Network 21 (VHA) | $119,619 | |
| Pharmacy order | Veterans Integrated Service Network 21 (VHA) | $13,291 | |
| Pemigatinib pemazyre | Veterans Integrated Service Network 21 (VHA) | $13,291 | |
| Pemigatinib | Veterans Integrated Service Network 21 (VHA) | $13,291 | |
| Pemigainib | Veterans Integrated Service Network 21 (VHA) | $12,725 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| U.s. Division | Rockville, MD | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Acer Therapeutics Inc. | Boston, MA | 456110 Pharmacies and Drug Retailers |
| Urogen Pharma Inc. | Princeton, NJ | 325414 Biological Product (except Diagnostic) Manufacturing |
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Servier Pharmaceuticals LLC | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Incyte Corporation is a global biopharmaceutical company specializing in the development and commercialization of innovative pharmaceutical products, with a primary focus on oncology and hematology treatments. The company has established a significant presence in the federal government marketplace, particularly with the Department of Veterans Affairs (VA), where it provides specialized pharmaceutical products through federal contract awards. Incyte is registered in SAM.gov as a for-profit corporate entity that manufactures pharmaceutical goods, with active federal contract registration through April 17, 2025.
Through its federal contract awards, Incyte Corporation has predominantly supplied Pemigatinib (marketed as Pemazyre), an oncology medication used to treat specific types of cancer, to various VA medical facilities across multiple Veterans Integrated Service Networks (VISNs). The company has consistently been awarded delivery orders under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, with contract values typically ranging from $12,000 to $63,000 per order. None of Incyte's federal contract awards have utilized set-aside designations, indicating the company competes in the unrestricted federal marketplace. The delivery orders have been firm fixed price contracts, primarily servicing VA medical centers in locations including Delaware, Oregon, Ohio, California, Connecticut, and other regions across the United States.
Incyte Corporation holds two primary federal contract Indefinite Delivery Vehicles (IDVs): a $541 million multiple-award Federal Supply Schedule contract and a $3.75 million single-award Blanket Purchase Agreement, both with the VA National Acquisition Center. The Federal Supply Schedule contract, set to expire on August 14, 2025, covers pharmaceuticals, drugs, and hematology-related products, with a specific emphasis on Pemazyre tablets in various dosages (4.5mg, 9mg, and 13.5mg). The Blanket Purchase Agreement, valid through November 20, 2025, is specifically dedicated to the supply of Pemazyre, allowing VA medical centers to efficiently procure this specialized oncology medication. These IDVs enable Incyte to provide critical pharmaceutical supplies to support healthcare services for veterans across the United States through pre-competed contract terms.
Quick answers
Is Incyte Corporation registered in SAM.gov?
Yes. Incyte Corporation's SAM.gov registration is active through March 26, 2027.
What is Incyte Corporation's CAGE code?
Incyte Corporation's CAGE code is 1F8A9, and its Unique Entity ID (UEI) is ZTM9U2G5VTK8.
Which contract vehicles does Incyte Corporation hold?
Incyte Corporation holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Incyte Corporation received in federal contracts?
Federal contracts obligated $223,353 to Incyte Corporation in fiscal years 2023 through 2027.
What is Incyte Corporation's most recent federal award?
Incyte Corporation's most recent federal contract award is Pemigatinib (36C26124N0749), from Veterans Integrated Service Network 21 (VHA), on July 2, 2024.
On GovTribe
See Incyte Corporation's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors